Early COVID-19 vaccine effectiveness of XBB.1.5 vaccine against hospitalisation and admission to intensive care, the Netherlands, 9 October to 5 December 2023.
Euro Surveill
; 29(1)2024 01.
Article
in En
| MEDLINE
| ID: mdl-38179623
ABSTRACT
We present early vaccine effectiveness (VE) estimates of the 2023 seasonal COVID-19 XBB.1.5 vaccine against COVID-19 hospitalisation and admission to an intensive care unit (ICU) in previously vaccinated adults ≥ 60 years in the Netherlands. We compared vaccination status of 2,050 hospitalisations including 92 ICU admissions with age group-, sex-, region- and date-specific population vaccination coverage between 9 October and 5 December 2023. VE against hospitalisation was 70.7% (95%â¯CI 66.6-74.3), VE against ICU admission was 73.3% (95%â¯CI 42.2-87.6).
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Vaccines
/
COVID-19
Limits:
Adult
/
Humans
Country/Region as subject:
Europa
Language:
En
Journal:
Euro Surveill
/
Euro surveill
/
Euro surveillance
Journal subject:
DOENCAS TRANSMISSIVEIS
Year:
2024
Document type:
Article
Affiliation country:
Países Bajos
Country of publication:
Suecia